Lower Efficacy Rate Of J&J’s COVID-19 Vaccine Presents ‘Messaging Challenge’

While vaccine has efficacy rate of 74% in the US, it completely prevented hospitalizations and deaths, which Fauci says is the most important result from a public health perspective. Vaccine findings cannot be compared given emergence of variants since Moderna and Pfizer conducted their studies, Janssen global head of R&D says.

Janssen vaccine and name (shutterstock)
J&J's COVID-19 vaccine demonstrates 66% overall effectivess, 100% protection against hospitalization and death • Source: Shutterstock

The lower efficacy rate of Johnson & Johnson’s COVID-19 vaccine compared to that of Pfizer Inc./BioNTech SE and Moderna, Inc.’s vaccine may impact uptake. But its 100% protection against COVID-19 related hospitalization and death is seen as hugely significant.

J&J announced on 29 January that its Phase III study of the single-dose vaccine demonstrated 66% effectiveness overall at preventing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet